Steven Wong, MD
Pulmonary Disease · San Diego, CANPI 1356363725
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 94.5% of the total across 186 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 28 manufacturers, the largest accounting for just 17.4% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $1,106 and has fallen 70.5% since, to $326 in 2025.
Across 186 payments — averaging $21.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$687
- Actelion Pharmaceuticals US, Inc.$667
- GSK$662
- AstraZeneca$483
- Insmed, Inc.$202
- Philips North America LLC$163
- plus $1K from 22 others
What the payments were for
- Food & beverage$3,72394%
- Education$2186%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 29 | $687 |
| Actelion Pharmaceuticals US, Inc. | 38 | $667 |
| GSK | 33 | $662 |
| AstraZeneca | 26 | $483 |
| Insmed, Inc. | 12 | $202 |
| Philips North America LLC | 3 | $163 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $152 |
| Karyopharm Therapeutics Inc. | 1 | $123 |
| Electromed, Inc. | 7 | $107 |
| Mallinckrodt Hospital Products Inc. | 3 | $101 |
| Grifols USA, LLC | 3 | $89 |
| Sanofi | 4 | $86 |
| Bayer | 3 | $68 |
| Paratek Pharmaceuticals, Inc. | 3 | $58 |
| Gilead | 1 | $31 |
| Johnson & Johnson | 2 | $31 |
| Daiichi Sankyo Inc. | 1 | $28 |
| Pfizer | 1 | $25 |
| Beigene USA, Inc. | 1 | $25 |
| Melinta Therapeutics, LLC | 1 | $24 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $21 |
| Sunovion Pharmaceuticals Inc. | 1 | $20 |
| E.r. Squibb & Sons, L.L.C. | 1 | $18 |
| Baxter Healthcare | 1 | $18 |
| AbbVie | 1 | $15 |
| Shire North American Group Inc | 1 | $14 |
| Circassia Inc. | 1 | $13 |
| Genentech USA, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,941 in reported general payments places this provider in the 65th percentile of 1,261 pulmonary disease providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OpsumitMacitentan | 11 | $136,912 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 165 | $122,417 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 72 | $53,551 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 75 | $39,799 |
| Pirfenidone | 13 | $37,289 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 26 | $17,876 |
| Breo ElliptaFluticasone/Vilanterol | 22 | $14,324 |
| EliquisApixaban | 17 | $10,753 |
| SymbicortBudesonide/Formoterol Fumarate | 37 | $10,201 |
| Advair HfaFluticasone Propion/Salmeterol | 30 | $8,856 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 119 | $4,391 |
| Wixela InhubFluticasone Propion/Salmeterol | 43 | $4,299 |
| Qvar RedihalerBeclomethasone Dipropionate | 14 | $3,282 |
| Ventolin HfaAlbuterol Sulfate | 33 | $2,847 |
| BreynaBudesonide/Formoterol Fumarate | 19 | $1,813 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta | $662 | $176,539262 claims |
| Actelion Pharmaceuticals US, Inc.Opsumit | $667 | $136,91211 claims |
| Boehringer IngelheimStiolto Respimat | $687 | $53,55172 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $483 | $28,07763 claims |
| PfizerEliquis | $25 | $10,75317 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 1,261 pulmonary disease providers in California.
Other pulmonary disease in San Diego
- George ChengSan Diego$291K
- Samir MakaniSan Diego$179K
- Shari BrazinskySan Diego$82K
- Samuel LouieSacramento$2.8M
- Shyamsunder SubramanianTracy$1.5M
- Toby MaherLos Angeles$1.3M
- Rajkumar DasguptaPasadena$930K
- Hoang leFountain Valley$814K
- Kevin FussellEncinitas$788K
- Revati ShreeniwasStanford$726K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.